It has shown promising clinical activity in patients with solid tumors harboring KRAS G12C alteration.30 The KRYSTAL-1 study31 showed that adagrasib had encouraging clinical activity in pretreated patients with PDAC, CC, and other solid tumors harboring a KRAS G12C alteration. Here, KRAS is linked to cholangiocarcinoma.